Showing 1981-1990 of 9096 results for "".
Long-Term Bimzelx Data Presented
https://practicaldermatology.com/videos/dermwire-tv/long-term-bimzelx-data-presented/35563/In this week's DermwireTV, new long-term data is presented for Bimzelx (bimekizumab-bkzx) for two indications; an analysis examines the correlation between proximity to tanning facilities and melanoma incidence; and in our C-Suite Chats feature, we hear from the Founder and CEO of Joya Health.DWTV Extra: New Tapinarof Data for AD
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-new-tapinarof-data-for-ad/33940/Linda Stein Gold, MD, discusses the results from the Phase 3 ADORING 3 open-label, long-term extension study evaluating tapinarof cream, 1% once daily in children as young as 2 and adults with atopic dermatitis, presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in OrlandoStep Therapy Reform Advocates Seek to Spread Awareness of Proposed Law
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/step-therapy-reform-advocates-seek-to-spread-awareness-of-proposed-law/33160/The Safe Step Act would stop insurance companies under certain circumstances from requiring alternative medications before covering biologics.What's New in Atopic Dermatitis?
https://practicaldermatology.com/programs/practical-dermatology/whats-new-in-atopic-dermatitis/33014/Emma Guttman, MD, PhD, professor and chair of dermatology at Mount Sinai, talks about the latest developments in treatments and therapies for atopic dermatitis.Dermwire TV Extra: The Global Access to Skin Health Observatory
https://practicaldermatology.com/videos/dermwire-tv/global-access-skin-health-observatory/29873/Esther Freeman, MD, PhD, Director of Global Health Dermatology at Massachusetts General Hospital and Harvard Medical School, and Vice Chair of the International Foundation of Dermatology with the International League of Dermatological Societies (ILDS), talks with Practical Dermatology about her workSDPA: Sara Wilchowski Talks About Transitioning to Industry and Understanding How Nutraceuticals Can Help Patients
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-sara-wilchowski-talks-about-transitioning-to-industry-and-understanding-how-nutraceuticals-can-help-patients/29513/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Sara Wilchowski, DMSc, MPAS, PA-C. Wilchowski is currently a senior medical science liaison and joined a panel of MSLs to discuss the ins and outs of transitioning to industry. Following the panel, she gave a lFDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/videos/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.What are Dermatologists’ Obstacles to Buy and Bill?
https://practicaldermatology.com/conferences/maui-derm-2024/what-are-dermatologists-obstacles-to-buy-and-bill/20241/Challenges with fee schedules have prompted many dermatologists to consider the buy and bill model. In a conversation between Practical Dermatology’s Chief Medical Editor Neal Bhatia, MD and Mark Kaufmann, MD, associate clinical professor at Mount Sinai, the doctors discuss some of the opportunitiesTo Sell or Not to Sell to Private Equity?
https://practicaldermatology.com/conferences/scale-2023/to-sell-or-not-to-sell-to-private-equity/20195/Joel L. Cohen, MD, and George Hruza MD, discuss the pros and cons of selling to private equity. Pros include back-office support and better pricing on technology and supplies, while cons can include giving up autonomy.Weighing the Safety of Sunscreens
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-safety-of-sunscreens/20172/Adam Friedman, MD, provides compelling reasons to question the recent studies on sunscreen safety.